Argenx (ARGX) said Monday it plans to advance the clinical development of ARGX-119 to a registrational study in patients with congenital myasthenic syndromes.
The treatment showed a favorable safety and tolerability profile in a phase 1b study, which was its primary endpoint, the company said.
Congenital myasthenic syndromes are a rare group of congenital neuromuscular disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.